NewAmsterdam Pharma Co NV
NAMS
Company Profile
Business description
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Contact
Gooimeer 2-35
NaardenNH1411 DC
NLDT: +31 352062971
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
77
Stocks News & Analysis
stocks
New production imminent for undervalued ASX gas play
LNG project receives first commissioning gas.
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.
stocks
Why I dislike dividend stocks
If you need income then buying dividend stocks makes perfect sense. But if you don’t then it makes little sense because it’s likely to limit building real wealth. Here’s what you should do instead.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,293.20 | 45.10 | -0.48% |
| CAC 40 | 8,189.52 | 0.93 | 0.01% |
| DAX 40 | 23,830.99 | 441.20 | -1.82% |
| Dow JONES (US) | 46,190.61 | 238.37 | 0.52% |
| FTSE 100 | 9,348.01 | 88.08 | -0.93% |
| HKSE | 25,247.10 | 641.41 | -2.48% |
| NASDAQ | 22,679.97 | 117.44 | 0.52% |
| Nikkei 225 | 47,582.15 | 695.59 | -1.44% |
| NZX 50 Index | 13,289.21 | 99.89 | -0.75% |
| S&P 500 | 6,664.01 | 34.94 | 0.53% |
| S&P/ASX 200 | 8,995.30 | 34.70 | -0.38% |
| SSE Composite Index | 3,839.76 | 76.47 | -1.95% |